Current concepts in the assessment and treatment of Hepatic Encephalopathy

QJM: An International Journal of Medicine

Volumn 103, Issue 1, 2009, Pages 9-16

  Cash, W J ^a   McConville, P ^b   McDermott, E ^a   McCormick, P A ^a   Callender, M E ^b   McDougall, N I ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACARBOSE; AMMONIA; ANTIBIOTIC AGENT; BENZODIAZEPINE RECEPTOR; BRANCHED CHAIN AMINO ACID; BROMOCRIPTINE; DISACCHARIDE; DOPAMINE RECEPTOR STIMULATING AGENT; ENEMA; FLUMAZENIL; LACTITOL; LACTULOSE; LEVODOPA; MANGANESE; METRONIDAZOLE; NEOMYCIN; NEUROTRANSMITTER; ORNITHINE ASPARTATE; PHOSPHATE; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN; ZINC;

BRAIN INJURY; CLINICAL TRIAL; DIET; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER SUPPORT; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; THEORY;

EID: 77950309824     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp152     Document Type: Review

References (40)

1. Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion 2006; 73(Suppl 1):86-93.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-21.
3. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72:573-83.
4. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008; 28: 1019-32.
5. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337:473-9.
6. Haussinger D, Kircheis G, Fischer R, Schliess F, Vom DS. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32:1035-8.
7. Watanabe A, Takei N, Higashi T, Shiota T, Nakatsukasa H, Fujiwara M, et al. Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy. Biochem Med 1984; 32:225-31.
8. Mardini H, Saxby BK, Record CO. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008; 135:1582-90.
9. Ahboucha S, Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 2004; 19:331-43.
10. Capocaccia L, Cangiano C, Cascino A, Calcaterra V, Cardelli P, Rossi FF. Influence of phenylethanolamine on octopamine plasma determination in hepatic encephalopathy. Clin Chim Acta 1979; 93:371-6.
11. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80:77-91.
12. Lozeva V, Montgomery JA, Tuomisto L, Rocheleau B, Pannunzio M, Huet PM, et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004; 40:742-8.
13. Lozeva-Thomas V. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis 2004; 19:413-20.
14. Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura SI, Watanabe A, et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 2001; 55:349-55.
15. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23:1084-92.
16. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003; 23:259-69.
17. Uribe M, Moran S, de la MG. [Dietetic manipulations in patients with hepatic encephalopathy]. Rev Gastroenterol Mex 1994; 59:74-8.
18. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41:38-43.
19. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328:1046.
20. Shawcross DL, Jalan R. Treatment of hepatic encephalopathy: it's not lactulose. BMJ 2004; 329:112.
21. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993; 38:916-22.
22. Ratnaike RN, Hicks EP, Hislop IG. The rectal administration of lactulose. Aust N Z J Med 1975; 5:137-40.
23. Van Waes L, van Egmond J, Demeulenaere L. Emergency treatment of portal-systemic encephalopathy with lactulose enemas. A controlled study. Acta Clin Belg 1979; 34:122-9.
24. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992; 15:222-8.
25. Berk DP, Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970; 73:393-6.
26. Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006; 73(Suppl 1):94-101.
27. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio BC. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49:53-62.
28. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12:203-8.
29. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16:138-44.
30. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995; 13:274-81.
31. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46:399-407.
32. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13:109-18.
33. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002; 17:221-7.
34. Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006; 5:281-8.
35. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006; 136:295S-8S.
36. Lock BG, Pandit K. Evidence-based emergency medicine/systematic review abstract. Is flumazenil an effective treatment for hepatic encephalopathy? Ann Emerg Med 2006; 47:286-8.
37. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289:217-22.
38. Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3:184-91.
39. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103:1707-15.
40. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20:506-11.